DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-5.76%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.49B
AUM Growth
+$4.49B
(-7.1%)
Cap. Flow
+$226M
Cap. Flow
% of AUM
5.04%
Top 10 Holdings %
Top 10 Hldgs %
44.77%
Holding
120
New
16
Increased
17
Reduced
12
Closed
11
Top Buys
| 1 |
Catalyst Pharmaceutical
CPRX
|
$74.1M |
| 2 |
Viatris
VTRS
|
$66.7M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$44.3M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$39.7M |
| 5 |
Owens & Minor
OMI
|
$39.1M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$46.7M |
| 2 |
Phreesia
PHR
|
$44.2M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$31.5M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
$22.5M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$20.8M |
Sector Composition
| 1 | Healthcare | 62.79% |
| 2 | Financials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $522M | 11.63% | 19,991,024 | – | – |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $177M | 3.94% | 1,744,714 +232,000 | +15% | +$23.5M |
|
|
3
Catalyst Pharmaceutical
CPRX
$2.52B
| $172M | 3.83% | 10,355,099 +4,470,651 | +76% | +$74.1M |
|
|
4
Viatris
VTRS
$12.3B
| $163M | 3.63% | 16,935,997 +6,935,997 | +69% | +$66.7M |
|
5
AdaptHealth
AHCO
$1.28B
| $132M | 2.94% | 10,594,914 +2,968,000 | +39% | +$36.9M |
|
|
AMED
6
DELISTED
Amedisys
AMED
| $109M | 2.43% | 1,483,179 +347,099 | +31% | +$25.5M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $80.6M | 1.8% | 5,218,638 +2,869,410 | +122% | +$44.3M |
|
8
Larimar Therapeutics
LRMR
$310M
| $76.7M | 1.71% | 16,941,357 | – | – |
|
9
ARS Pharmaceuticals
SPRY
$1.15B
| $72.1M | 1.61% | 11,077,927 | – | – |
|
10
Centene
CNC
$14.3B
| $68M | 1.51% | 1,075,000 +510,000 | +90% | +$32.2M |
|
|
SILK
11
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $67.5M | 1.51% | 1,725,640 +329,000 | +24% | +$12.9M |
|
|
12
Amylyx Pharmaceuticals
AMLX
$836M
| $58.2M | 1.3% | 1,984,333 -708,667 | -26% | -$20.8M |
|
|
13
Owens & Minor
OMI
$378M
| $56.3M | 1.25% | 3,867,455 +2,688,455 | +228% | +$39.1M |
|
14
Mirum Pharmaceuticals
MIRM
$3.71B
| $48.8M | 1.09% | 2,032,335 | – | – |
|
15
Brookdale Senior Living
BKD
$1.83B
| $48.4M | 1.08% | 16,406,047 +3,726,396 | +29% | +$11M |
|
16
Enhabit
EHAB
$399M
| $47.3M | 1.05% | 3,398,746 +402,746 | +13% | +$5.6M |
|
17
HilleVax
HLVX
$105M
| $46.8M | 1.04% | 2,833,690 +139,589 | +5% | +$2.31M |
|
18
Merus
MRUS
$4.98B
| $43.8M | 0.98% | 2,380,438 | – | – |
|
|
CMAX
19
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $42.3M | 0.94% | 15,861,090 | – | – |
|
|
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
| $40.7M | 0.91% | 1,579,349 +546,349 | +53% | +$14.1M |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $39.7M | 0.89% | +734,000 | New | +$39.7M |
|
|
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $36.6M | 0.82% | 1,504,578 -1,920,274 | -56% | -$46.7M |
|
23
NewAmsterdam Pharma
NAMS
$2.71B
| $33.6M | 0.75% | 2,535,723 +55,524 | +2% | +$736K |
|
24
Cogent Biosciences
COGT
$1.69B
| $32M | 0.71% | 2,966,345 | – | – |
|
25
Evolus
EOLS
$494M
| $30.2M | 0.67% | 3,569,000 +250,000 | +8% | +$2.12M |
|